Praxis Precision’s tremor-drug trial succeeds where others have failed. The stock is skyrocketing.
Shares of Praxis Precision Medicines have hit their highest intraday level since March 2022.
AI brief
Pulse reads the full article- What happened
- Why it matters
- What to watch
Sign in to get the AI brief. Pulse explains what happened, why it matters, what to watch and who's exposed. Free for members.
Sign in to read the brief
